MarketCapExport financials
Bio-Rad Laboratories (BIO)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Bio-Rad Laboratories Balance Sheet 2025-2007 | BIO
Brief overview of Bio-Rad Laboratories's balance sheet structure
The review uses the five latest available annual reports between 2020 and 2024.
Assets fell from $13 billion to $9.4 billion. This may reflect either deliberate optimization or a reduction in business scale.
Asset growth of -27.8% came with a -9.6% rise in liabilities. Financial leverage became more prominent.
Internal capital represents 70.2% of the balance sheet, previously 76.2%. This is a strong capital position.
Net debt to equity stands at 0.11x; the current burden does not look excessive.
The cash reserve occupies 5.2% of the balance sheet, previously 5.1%. It is one marker of short-term resilience.
Accumulated earnings ended at $7.4 billion, a change of -20%. They remain an important part of the capital base.
Overall assessment
Bio-Rad Laboratories's balance sheet presents a mixed picture: strengths coexist with a limited cushion. Future capital and debt trends are particularly important.
Annual Balance Sheet Bio-Rad Laboratories
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
708 M | 754 M | 836 M | 800 M | -424 M | -613 M | -221 M | 7.9 M | 51.2 M | -21.7 M | -21.5 M | 22.7 M | 106 M | 271 M | 158 M | 57.6 M | - | - | - |
Long Term Debt |
1.2 B | 1.2 B | 1.2 B | 1.2 B | 10.5 M | 12.3 M | 13.6 M | 439 M | 435 M | 434 M | 436 M | 436 M | 436 M | 732 M | 732 M | 731 M | - | - | - |
Long Term Debt Current |
36.1 M | 41.7 M | 40.4 M | 36.3 M | 36.4 M | 36.5 M | 35.4 M | - | - | - | - | - | 200 K | 200 K | 600 K | 233 M | 738 M | - | - |
Total Non Current Liabilities |
2.61 B | 2.33 B | 3.04 B | 3.32 B | 3.43 B | 2.46 B | 1.35 B | 1.14 B | 840 M | 792 M | 780 M | 709 M | 715 M | 956 M | 893 M | 856 M | 837 M | - | - |
Total Current Liabilities |
517 M | 468 M | 523 M | 569 M | 681 M | 632 M | 905 M | 451 M | 503 M | 471 M | 441 M | 447 M | 487 M | 470 M | 459 M | 667 M | 420 M | - | - |
Total Liabilities |
3.12 B | 2.79 B | 3.56 B | 3.89 B | 4.11 B | 3.09 B | 2.25 B | 1.59 B | 1.34 B | 1.26 B | 1.22 B | 1.16 B | 1.2 B | 1.43 B | 1.35 B | 1.52 B | 1.26 B | - | - |
Deferred Revenue |
48.9 M | 47.8 M | 51.1 M | 52.2 M | 50.9 M | 42.5 M | 33.7 M | 26.9 M | 28.2 M | 31 M | 29.7 M | 26.7 M | 26.4 M | 26.3 M | 24.3 M | 20.6 M | - | - | - |
Retained Earnings |
8.18 B | 7.42 B | 9.26 B | 9.9 B | 13.5 B | 9.27 B | 5.47 B | 3.72 B | 1.83 B | 1.84 B | 1.81 B | 1.69 B | 1.61 B | 1.52 B | 1.36 B | 1.18 B | 996 M | - | - |
Total Assets |
10.6 B | 9.36 B | 12.3 B | 13.5 B | 17.8 B | 13 B | 8.01 B | 5.61 B | 4.27 B | 3.85 B | 3.71 B | 3.34 B | 3.39 B | 3.44 B | 3.1 B | 3.06 B | 2.54 B | - | - |
Cash and Cash Equivalents |
530 M | 488 M | 404 M | 434 M | 471 M | 662 M | 661 M | 432 M | 384 M | 456 M | 458 M | 413 M | 332 M | 463 M | 574 M | 907 M | 650 M | 205 M | 162 M |
Book Value |
7.45 B | 6.57 B | 8.74 B | 9.62 B | 13.7 B | 9.88 B | 5.76 B | 4.02 B | 2.93 B | 2.59 B | 2.49 B | 2.19 B | 2.19 B | 2.01 B | 1.74 B | 1.54 B | 1.28 B | - | - |
Total Shareholders Equity |
7.45 B | 6.57 B | 8.74 B | 9.62 B | 13.7 B | 9.89 B | 5.76 B | 4.02 B | 2.93 B | 2.58 B | 2.49 B | 2.19 B | 2.19 B | 2.01 B | 1.74 B | 1.54 B | 1.26 B | 1.07 B | 1.01 B |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Bio-Rad Laboratories
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q4 | 2010-Q3 | 2010-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
128 M | 133 M | 139 M | 146 M | 156 M | 165 M | 126 M | 131 M | 144 M | 151 M | 160 M | 166 M | 167 M | 147 M | 147 M | 154 M | 147 M | 159 M | 170 M | 176 M | 177 M | 164 M | 168 M | 175 M | 172 M | 173 M | 175 M | 176 M | 193 M | 188 M | 193 M | 439 M | 439 M | 439 M | 435 M | 435 M | 434 M | 434 M | 434 M | 434 M | 434 M | 434 M | 434 M | 434 M | 436 M | 436 M | 436 M | 436 M | 436 M | 436 M | 436 M | 436 M | 436 M | 733 M | 733 M | 733 M | 732 M | 732 M | 732 M | 732 M | 732 M | 732 M | 731 M | 964 M | 734 M | 734 M |
Total Non Current Liabilities |
2.21 B | 2.12 B | 2.02 B | 2.61 B | 2.44 B | 2.54 B | 2.34 B | 2.33 B | 2.62 B | 2.42 B | 3.09 B | 3.04 B | 2.92 B | 2.95 B | 3.31 B | 3.32 B | 3.03 B | 3.15 B | 3.54 B | 3.43 B | 3.97 B | 2.94 B | 2.71 B | 2.46 B | 2.21 B | 1.82 B | 1.52 B | 1.35 B | 1.61 B | 1.71 B | 1.55 B | 1.14 B | 1.37 B | 1.3 B | 1.27 B | 840 M | 871 M | 877 M | 838 M | 800 M | 874 M | 850 M | 808 M | 778 M | 801 M | 763 M | 711 M | 709 M | 706 M | 738 M | 728 M | 715 M | 693 M | 981 M | 979 M | 956 M | 934 M | 899 M | 904 M | 893 M | 861 M | 875 M | 868 M | 856 M | 843 M | 835 M |
Total Liabilities |
3.18 B | 3.08 B | 2.94 B | 3.12 B | 2.96 B | 3.09 B | 2.85 B | 2.79 B | 3.12 B | 2.91 B | 3.56 B | 3.56 B | 3.48 B | 3.53 B | 3.9 B | 3.89 B | 3.6 B | 3.76 B | 4.19 B | 4.11 B | 4.62 B | 3.52 B | 3.32 B | 3.09 B | 3.2 B | 2.74 B | 2.39 B | 2.25 B | 2.05 B | 2.16 B | 2 B | 1.59 B | 1.82 B | 1.75 B | 1.73 B | 1.34 B | 1.34 B | 1.33 B | 1.25 B | 1.27 B | 1.32 B | 1.26 B | 1.21 B | 1.22 B | 1.24 B | 1.17 B | 1.13 B | 1.16 B | 1.21 B | 1.22 B | 1.21 B | 1.2 B | 1.16 B | 1.41 B | 1.43 B | 1.43 B | 1.37 B | 1.32 B | 1.35 B | 1.35 B | 1.28 B | 1.32 B | 1.3 B | 1.52 B | 1.25 B | 1.22 B |
Deferred Revenue |
47.1 M | 52.5 M | 56.3 M | 48.9 M | 50.2 M | 54.4 M | 53.8 M | 47.8 M | 48.9 M | 52 M | 55.1 M | 51.1 M | 49.1 M | 53.7 M | 56.9 M | 52.2 M | 58 M | 60.5 M | 59.3 M | 50.9 M | 47.9 M | 47.5 M | 48 M | 42.5 M | 40.9 M | 38.1 M | 42.5 M | 33.7 M | 33.7 M | 33.7 M | - | 26.9 M | - | - | - | 28.2 M | - | - | - | 31 M | - | - | - | 29.7 M | - | - | - | 26.7 M | - | - | - | 26.4 M | - | - | - | 26.3 M | - | - | - | 24.3 M | - | - | - | 20.6 M | - | - |
Retained Earnings |
8.48 B | 8.02 B | 7.65 B | 8.18 B | 7.46 B | 7.8 B | 7.48 B | 7.42 B | 8.13 B | 7.48 B | 9.64 B | 9.26 B | 8.91 B | 8.8 B | 9.97 B | 9.9 B | 9.05 B | 9.21 B | 10.1 B | 13.5 B | 15.1 B | 11.2 B | 10.2 B | 9.27 B | 8.43 B | 7.12 B | 6.16 B | 5.47 B | 4.92 B | 5.18 B | 4.59 B | 3.72 B | 4.55 B | 4.28 B | 4.01 B | 1.83 B | 1.88 B | 1.85 B | 1.85 B | 1.83 B | 1.86 B | 1.84 B | 1.82 B | 1.81 B | 1.76 B | 1.74 B | 1.71 B | 1.69 B | 1.66 B | 1.64 B | 1.61 B | 1.61 B | 1.58 B | 1.58 B | 1.54 B | 1.53 B | 1.48 B | 1.44 B | 1.39 B | 1.36 B | 1.3 B | 1.25 B | 1.21 B | 1.18 B | 1.11 B | 1.07 B |
Total Assets |
10.8 B | 10.3 B | 9.79 B | 10.6 B | 9.7 B | 10.2 B | 9.53 B | 9.36 B | 10.6 B | 9.69 B | 12.6 B | 12.3 B | 11.9 B | 12 B | 13.7 B | 13.5 B | 12.1 B | 12.7 B | 14.4 B | 17.8 B | 20 B | 15.1 B | 13.9 B | 13 B | 12 B | 10.1 B | 8.68 B | 8.01 B | 7.18 B | 7.65 B | 6.86 B | 5.61 B | 6.72 B | 6.39 B | 6.21 B | 4.27 B | 4.19 B | 4.14 B | 3.95 B | 3.85 B | 4.02 B | 3.87 B | 3.75 B | 3.71 B | 3.67 B | 3.53 B | 3.33 B | 3.34 B | 3.39 B | 3.47 B | 3.44 B | 3.39 B | 3.28 B | 3.48 B | 3.46 B | 3.44 B | 3.3 B | 3.17 B | 3.19 B | 3.1 B | 2.97 B | 3.04 B | 2.91 B | 3.06 B | 2.68 B | 2.53 B |
Cash and Cash Equivalents |
467 M | 519 M | 509 M | 532 M | 398 M | 372 M | 523 M | 490 M | 412 M | 408 M | 434 M | 404 M | 458 M | 390 M | 465 M | 434 M | 518 M | 597 M | 803 M | 471 M | 865 M | 737 M | 678 M | 667 M | 845 M | 612 M | 608 M | 663 M | 563 M | 583 M | 459 M | 434 M | 436 M | 404 M | 408 M | 385 M | 330 M | 323 M | 293 M | 457 M | 418 M | 419 M | 419 M | 459 M | 507 M | 450 M | 426 M | 413 M | 425 M | 385 M | 365 M | 332 M | 292 M | 367 M | 369 M | 463 M | 426 M | 456 M | 534 M | 574 M | 671 M | 670 M | 628 M | 907 M | 631 M | 614 M |
Book Value |
7.6 B | 7.17 B | 6.85 B | 7.45 B | 6.74 B | 7.13 B | 6.68 B | 6.57 B | 7.49 B | 6.78 B | 9.05 B | 8.74 B | 8.42 B | 8.45 B | 9.76 B | 9.62 B | 8.45 B | 8.92 B | 10.2 B | 13.7 B | 15.3 B | 11.6 B | 10.6 B | 9.88 B | 8.83 B | 7.35 B | 6.29 B | 5.76 B | 5.13 B | 5.49 B | 4.86 B | 4.02 B | 4.9 B | 4.64 B | 4.49 B | 2.93 B | 2.85 B | 2.81 B | 2.71 B | 2.58 B | 2.7 B | 2.61 B | 2.54 B | 2.49 B | 2.43 B | 2.36 B | 2.2 B | 2.19 B | 2.18 B | 2.25 B | 2.23 B | 2.19 B | 2.12 B | 2.07 B | 2.03 B | 2.02 B | 1.94 B | 1.85 B | 1.84 B | 1.74 B | 1.69 B | 1.73 B | 1.61 B | 1.54 B | 1.43 B | 1.3 B |
Total Shareholders Equity |
7.6 B | 7.17 B | 6.85 B | 7.45 B | 6.74 B | 7.13 B | 6.68 B | 6.57 B | 7.49 B | 6.78 B | 9.05 B | 8.74 B | 8.42 B | 8.45 B | 9.76 B | 9.62 B | 8.48 B | 8.95 B | 10.2 B | 13.7 B | 15.3 B | 11.6 B | 10.6 B | 9.89 B | 8.83 B | 7.35 B | 6.29 B | 5.76 B | 5.13 B | 5.49 B | 4.86 B | 4.02 B | 4.9 B | 4.64 B | 4.49 B | 2.93 B | 2.85 B | 2.81 B | 2.71 B | 2.58 B | 2.7 B | 2.61 B | 2.54 B | 2.49 B | 2.43 B | 2.36 B | 2.2 B | 2.19 B | 2.18 B | 2.25 B | 2.23 B | 2.19 B | 2.12 B | 2.07 B | 2.03 B | 2.02 B | 1.94 B | 1.85 B | 1.84 B | 1.75 B | 1.69 B | 1.73 B | 1.61 B | 1.54 B | 1.43 B | 1.3 B |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Bio-Rad Laboratories, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Australia
USA
Israel
France
Britain
